Recent advances in recurrent hepatocellular carcinoma therapy

doi:10.4254/wjh.v15.i4.460

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3422)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

187

WORD

HTML

2195

Figures (1-1)

347

Sum=2767

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

162

Download

361

Sum=523

Apr 27, 2023 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Apr 27, 2023; 15(4): 460-476
Published online Apr 27, 2023. doi: 10.4254/wjh.v15.i4.460

Open in New Tab Full Size Figure Download Figure

Figure 1 Mechanism of action of immune cells under investigation for recurrence of hepatocellular carcinoma. Early-relapse hepatocellular carcinoma displays decreased regulatory T cells, and higher dendritic cells and CD8+T cells. FoxP3(+) regulatory T cells encourage a gradual decline in CD4+ cytotoxic T cells, which contributes to poorer survival and high recurrence rates. OS: Overall survival; RFS: Relapse-free survival; DC: Dendritic cells; NK: Natural killer cell.

Citation: Gao YX, Ning QQ, Yang PX, Guan YY, Liu PX, Liu ML, Qiao LX, Guo XH, Yang TW, Chen DX. Recent advances in recurrent hepatocellular carcinoma therapy. World J Hepatol 2023; 15(4): 460-476
URL: https://www.wjgnet.com/1948-5182/full/v15/i4/460.htm
DOI: https://dx.doi.org/10.4254/wjh.v15.i4.460